Sanctuary Advisors LLC Invests $2.10 Million in Smith & Nephew SNATS, Inc. $SNN

Sanctuary Advisors LLC acquired a new stake in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 33,468 shares of the medical equipment provider’s stock, valued at approximately $2,099,000.

Several other hedge funds have also recently made changes to their positions in SNN. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of Smith & Nephew SNATS in the second quarter worth about $13,812,000. Grandfield & Dodd LLC purchased a new stake in Smith & Nephew SNATS in the second quarter valued at approximately $13,192,000. Teachers Retirement System of The State of Kentucky boosted its position in Smith & Nephew SNATS by 51.0% in the first quarter. Teachers Retirement System of The State of Kentucky now owns 905,100 shares of the medical equipment provider’s stock valued at $28,764,000 after buying an additional 305,600 shares during the last quarter. BlackRock Inc. purchased a new position in Smith & Nephew SNATS during the 2nd quarter worth approximately $505,323,000. Finally, Deutsche Bank AG acquired a new stake in Smith & Nephew SNATS during the 2nd quarter valued at approximately $33,563,000. 25.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. The Goldman Sachs Group reiterated a “buy” rating on shares of Smith & Nephew SNATS in a research note on Monday, May 25th. Morgan Stanley reaffirmed an “overweight” rating on shares of Smith & Nephew SNATS in a report on Wednesday, August 5th. Weiss Ratings downgraded Smith & Nephew SNATS from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, June 11th. Wall Street Zen upgraded Smith & Nephew SNATS from a “hold” rating to a “buy” rating in a research note on Monday. Finally, Zacks Research cut Smith & Nephew SNATS from a “hold” rating to a “strong sell” rating in a report on Friday, August 7th. Two equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $30.93.

Smith & Nephew SNATS Stock Performance

Shares of NYSE SNN opened at $29.32 on Thursday. The company has a quick ratio of 1.11, a current ratio of 2.14 and a debt-to-equity ratio of 0.62. The firm’s 50 day simple moving average is $30.26 and its 200-day simple moving average is $31.74. Smith & Nephew SNATS, Inc. has a 12 month low of $28.56 and a 12 month high of $38.79.

Smith & Nephew SNATS Dividend Announcement

The company also recently declared a dividend, which will be paid on Friday, November 6th. Investors of record on Friday, October 2nd will be given a dividend of $0.312 per share. This represents a yield of 205.0%. The ex-dividend date is Friday, October 2nd.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.